The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Increased nuclear factor kappaB (NF-kappaB) activity is associated with increased tumor cell survival in multiple myeloma. The function of NF-kappaB is inhibited through binding to its inhibitor, IkappaB. Release of activated NF-kappaB follows proteasome-mediated degradation of IkappaB resulting from phosphorylation of the inhibitor and, finally, conjugation with ubiquitin. We report that myeloma cells have enhanced IkappaBalpha phosphorylation and increased NF-kappaB activity compared with normal hematopoietic cells. The proteasome inhibitor PS-341 blocked nuclear translocation of NF-kappaB, blocked NF-kappaB DNA binding, and demonstrated consistent antitumor activity against chemoresistant and chemosensitive myeloma cells. The sensitivity of chemoresistant myeloma cells to chemotherapeutic agents was markedly increased (100,000-1,000,000-fold) when combined with a noncytotoxic dose of PS-341 without affecting normal hematopoietic cells. Similar effects were observed using a dominant negative super-repressor for IkappaBalpha. Thus, these results suggest that inhibition of NF-kappaB with PS-341 may overcome chemoresistance and allow doses of chemotherapeutic agents to be markedly reduced with antitumor effects without significant toxicity.

[1]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Berenson,et al.  Identification of polymorphisms of the IκBα gene associated with an increased risk of multiple myeloma , 2002 .

[3]  L. Moscinski,et al.  An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. , 2001, Cancer research.

[4]  L. Liu,et al.  Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. , 2001, Cancer research.

[5]  P. Vaagenes,et al.  [Steroid treatment of shock lung--tune for re-evaluation?]. , 2001, Tidsskrift for Den Norske Laegeforening.

[6]  P. Elliott,et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. , 2001, Cancer research.

[7]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[8]  R. Kyle,et al.  Update on the treatment of multiple myeloma. , 2001, The oncologist.

[9]  S. Alkan,et al.  Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. , 2000, Human pathology.

[10]  J. Puzas,et al.  Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. , 2000, Cancer research.

[11]  Korey R. Johnson,et al.  Nuclear Factor-κB/IκB Signaling Pathway May Contribute to the Mediation of Paclitaxel-induced Apoptosis in Solid Tumor Cells , 2000 .

[12]  S-G Hwang,et al.  Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition , 2000, Leukemia.

[13]  S. Han,et al.  NF-κB Activation Is Related to the Resistance of Lung Cancer Cells to TNF-α-Induced Apoptosis , 2000 .

[14]  P. Elliott,et al.  Proteasome Inhibition: a New Strategy in Cancer Treatment , 2000, Investigational New Drugs.

[15]  P. Elliott,et al.  Proteasome inhibition measurements: clinical application. , 2000, Clinical chemistry.

[16]  B. Rayet,et al.  Aberrant rel/nfkb genes and activity in human cancer , 1999, Oncogene.

[17]  T. Gilmore,et al.  Control of apoptosis by Rel/NF-κB transcription factors , 1999, Oncogene.

[18]  G. Haegeman,et al.  Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-kappaB-dependent mechanism. , 1999, Molecular pharmacology.

[19]  H. Kantarjian,et al.  Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1999, Seminars in hematology.

[20]  F. Vittimberga,et al.  Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. , 1999, Surgery.

[21]  R. Hay,et al.  Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα , 1999, Oncogene.

[22]  B. Barlogie,et al.  Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. , 1999, Blood.

[23]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[24]  R. Weichselbaum,et al.  Combined effects of angiostatin and ionizing radiation in antitumour therapy , 1998, Nature.

[25]  R. Bell,et al.  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Ghosh,et al.  Signal transduction through NF-κB , 1998 .

[27]  R. Weichselbaum,et al.  Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. , 1997, Cancer research.

[28]  A. Rubagotti,et al.  A Randomized Trial of Chemotherapy with or without Estrogenic Recruitment in Locally Advanced Breast Cancer , 1997, Tumori.

[29]  A. Israël,et al.  IκB proteins: structure, function and regulation , 1997 .

[30]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[31]  D. White,et al.  Rel/NF-kappaB/IkappaB proteins and cancer. , 1996, Oncogene.

[32]  M A Wainberg,et al.  Regulation of Human Immunodeficiency Virus Type 1 and Cytokine Gene Expression in Myeloid Cells by Nf-␬b/rel Transcription Factors , 2022 .

[33]  R. Hay,et al.  Regulation of the DNA binding activity of NF-κB , 1995 .

[34]  L. Rosen,et al.  Multiple myeloma and chronic lymphocytic leukemia , 1995, Current opinion in hematology.

[35]  M. Rocchi,et al.  Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. , 1994, Blood.

[36]  Tom Maniatis,et al.  The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB , 1994, Cell.

[37]  S. Goodbourn,et al.  Proteolytic degradation of MAD3 (IϰBα) and enhanced processing of the NF-ϰB precursor p105 are obligatory steps in the activation of NF-ϰB , 1993 .

[38]  A. Baldwin,et al.  The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. , 1993, Genes & development.

[39]  Y. Ben-Neriah,et al.  Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB , 1993, Nature.

[40]  G. Franzoso,et al.  Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  W. Schaffner,et al.  Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. , 1989, Nucleic acids research.

[42]  J. Tobias,et al.  Management of multiple myeloma. , 1987, British journal of hospital medicine.

[43]  S. Masters,et al.  14-3-3 proteins: structure, function, and regulation. , 2000, Annual review of pharmacology and toxicology.

[44]  T. Hamblin,et al.  Management of multiple myeloma today. , 1999, Seminars in hematology.

[45]  K. Arastéh,et al.  Malignant gastrointestinal lymphomas in patients with AIDS. , 1997, Digestion.

[46]  R. Alexanian,et al.  Management of multiple myeloma. , 1995, Seminars in hematology.

[47]  Mutual regulation of the transcriptional activator NF-cB and its inhibitor, I1cB-a , 2022 .